title: Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck.
abstract: BACKGROUND
  Postopertative adjuvant chemoradiotherapy recently became an established modality for patients with selected high-risk locally advanced head and neck cancers. The optimal treatment of unknown primary squamous cell cancer of the head and neck (SCCHN) continues to be controversial, since major randomized studies excluded those patients.
  
  
  METHODS
  We conducted a retrospective review of patients treated during 1995 to 2002 for unknown primary SCCHN. All patients were treated with a neck dissection followed by concurrent high-dose cisplatin (100 mg/m(2)) and bilateral neck radiotherapy.
  
  
  RESULTS
  Thirty-seven patients were identified with nodal disease distribution of N1 (5%), N2a (22%), N2b (41%), N2c (8%), N3 (22%), and Nx (3%). Modified neck dissection was done on the majority (30/37 = 81%) of patients. With a median follow-up of 42 months among the survivors, very few patients had regional recurrence (5%) or distant failure (11%), and 89% of patients were alive. The actuarial 5-year overall survival rate could not be estimated because there were no deaths beyond 20 months after surgery. Substantial yet acceptable acute and late morbidities were demonstrated in this cohort of patients.
  
  
  CONCLUSIONS
  Postoperative chemoradiotherapy is of potential benefit to patients with unknown primary SCCHN by improving survival and reducing failures. This treatment warrants further prospective evaluation.
authors.affiliation: Division of Hematology/Oncology and Transplantation (HOT), Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
authors.forename: Nasfat J
authors.initials: NJ
authors.lastname: Shehadeh
authors.forename: John F
authors.initials: JF
authors.lastname: Ensley
authors.forename: Omer
authors.initials: O
authors.lastname: Kucuk
authors.forename: Carri
authors.initials: C
authors.lastname: Black
authors.forename: George H
authors.initials: GH
authors.lastname: Yoo
authors.forename: John
authors.initials: J
authors.lastname: Jacobs
authors.forename: Ho-Sheng
authors.initials: HS
authors.lastname: Lin
authors.forename: Lance K
authors.initials: LK
authors.lastname: Heilbrun
authors.forename: Daryn
authors.initials: D
authors.lastname: Smith
authors.forename: Harold
authors.initials: H
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000556:secondary* / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection; D009382:Neoplasms, Unknown Primary / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin